Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3050258 · 2 trials · 2 indications
Clinically significant events were defined as serious and other nonserious adverse events (AE) related to study drug. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Arm | Type | Description |
|---|---|---|
| LY3050258 | EXPERIMENTAL | Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg. |
| Placebo | PLACEBO_COMPARATOR | Daily dose of placebo matching LY3050258 for 28 days. |
| Name | Type | Description |
|---|---|---|
| LY3050258 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Healthy males or healthy postmenopausal females, including Japanese participants * Body mass index (BMI) of 18 and 35 kilograms per square meter (kg/m\^2), inclusive Exclusion Criteria: * Abnormal siting blood pressure as determined by the investigator * Abnormality in the 1...
LY3050258 is an investigational small molecule being studied in healthy participants and healthy volunteers. It is in Phase 1 clinical development, with completed trials evaluating its effects in these populations. The drug is not approved and remains under investigation.
LY3050258 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker LLY. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy participants.
LY3050258 is in Phase 1 clinical development. It is an investigational small molecule, and its trials in healthy participants and healthy volunteers have been completed. The drug is not FDA approved and is still under clinical investigation.
LY3050258 has been studied in two completed Phase 1 clinical trials: NCT01929707 and NCT02121834, both titled 'A Study of LY3050258 in Healthy Participants.' These trials enrolled healthy participants and healthy volunteers in the United States, with a minimum age of 30 years.
LY3050258 is the primary name for this investigational small molecule developed by Eli Lilly and Company. No alternative names have been associated with this drug in the available clinical trial information.